Cargando…

Unexplained abdominal pain as a driver for inappropriate therapeutics: an audit on the use of intravenous proton pump inhibitors

Background. Proton pump inhibitors (PPIs) are currently the most effective agents for acid-related disorders. However, studies show that 25–75% of patients receiving intravenous PPIs had no appropriate justification, indicating high rates of inappropriate prescribing. Objective. To examine the appro...

Descripción completa

Detalles Bibliográficos
Autores principales: Lai, Pauline Siew Mei, Wong, Yin Yen, Low, Yong Chia, Lau, Hui Ling, Chin, Kin-Fah, Mahadeva, Sanjiv
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PeerJ Inc. 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4081131/
https://www.ncbi.nlm.nih.gov/pubmed/25024919
http://dx.doi.org/10.7717/peerj.451
_version_ 1782324073178595328
author Lai, Pauline Siew Mei
Wong, Yin Yen
Low, Yong Chia
Lau, Hui Ling
Chin, Kin-Fah
Mahadeva, Sanjiv
author_facet Lai, Pauline Siew Mei
Wong, Yin Yen
Low, Yong Chia
Lau, Hui Ling
Chin, Kin-Fah
Mahadeva, Sanjiv
author_sort Lai, Pauline Siew Mei
collection PubMed
description Background. Proton pump inhibitors (PPIs) are currently the most effective agents for acid-related disorders. However, studies show that 25–75% of patients receiving intravenous PPIs had no appropriate justification, indicating high rates of inappropriate prescribing. Objective. To examine the appropriate use of intravenous PPIs in accordance with guidelines and the efficacy of a prescribing awareness intervention at an Asian teaching institution. Setting. Prospective audit in a tertiary hospital in Malaysia. Method. Every 4th intravenous PPI prescription received in the pharmacy was screened against hospital guidelines. Interventions for incorrect indication/dose/duration were performed. Patients’ demographic data, medical history and the use of intravenous PPI were collected. Included were all adult inpatients prescribed intravenous PPI. Main Outcome Measure. Proportion of appropriate IV PPI prescriptions. Results. Data for 106 patients were collected. Most patients were male [65(61.3%)], Chinese [50(47.2%)], with mean age ± SD = 60.3 ± 18.0 years. Most intravenous PPI prescriptions were initiated by junior doctors from the surgical [47(44.3%)] and medical [42(39.6%)] departments. Only 50/106(47.2%) patients had upper gastrointestinal endoscopy/surgery performed to verify the source of bleeding. Unexplained abdominal pain [81(76.4%)] was the main driver for prescribing intravenous PPIs empirically, out of which 73(68.9%) were for suspected upper gastrointestinal bleed. Overall, intravenous PPI was found to be inappropriately prescribed in 56(52.8%) patients for indication, dose or duration. Interventions on the use of intravenous PPI were most effective when performed by senior doctors (100%), followed by clinical pharmacists (50%), and inpatient pharmacists (37.5%, p = 0.027). Conclusion. Inappropriate intravenous PPI usage is still prevalent despite the enforcement of hospital guidelines. The promotion of prescribing awareness and evidence-based prescribing through education of medical staff could result in more judicious use of intravenous PPI and dose-optimization.
format Online
Article
Text
id pubmed-4081131
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher PeerJ Inc.
record_format MEDLINE/PubMed
spelling pubmed-40811312014-07-14 Unexplained abdominal pain as a driver for inappropriate therapeutics: an audit on the use of intravenous proton pump inhibitors Lai, Pauline Siew Mei Wong, Yin Yen Low, Yong Chia Lau, Hui Ling Chin, Kin-Fah Mahadeva, Sanjiv PeerJ Gastroenterology and Hepatology Background. Proton pump inhibitors (PPIs) are currently the most effective agents for acid-related disorders. However, studies show that 25–75% of patients receiving intravenous PPIs had no appropriate justification, indicating high rates of inappropriate prescribing. Objective. To examine the appropriate use of intravenous PPIs in accordance with guidelines and the efficacy of a prescribing awareness intervention at an Asian teaching institution. Setting. Prospective audit in a tertiary hospital in Malaysia. Method. Every 4th intravenous PPI prescription received in the pharmacy was screened against hospital guidelines. Interventions for incorrect indication/dose/duration were performed. Patients’ demographic data, medical history and the use of intravenous PPI were collected. Included were all adult inpatients prescribed intravenous PPI. Main Outcome Measure. Proportion of appropriate IV PPI prescriptions. Results. Data for 106 patients were collected. Most patients were male [65(61.3%)], Chinese [50(47.2%)], with mean age ± SD = 60.3 ± 18.0 years. Most intravenous PPI prescriptions were initiated by junior doctors from the surgical [47(44.3%)] and medical [42(39.6%)] departments. Only 50/106(47.2%) patients had upper gastrointestinal endoscopy/surgery performed to verify the source of bleeding. Unexplained abdominal pain [81(76.4%)] was the main driver for prescribing intravenous PPIs empirically, out of which 73(68.9%) were for suspected upper gastrointestinal bleed. Overall, intravenous PPI was found to be inappropriately prescribed in 56(52.8%) patients for indication, dose or duration. Interventions on the use of intravenous PPI were most effective when performed by senior doctors (100%), followed by clinical pharmacists (50%), and inpatient pharmacists (37.5%, p = 0.027). Conclusion. Inappropriate intravenous PPI usage is still prevalent despite the enforcement of hospital guidelines. The promotion of prescribing awareness and evidence-based prescribing through education of medical staff could result in more judicious use of intravenous PPI and dose-optimization. PeerJ Inc. 2014-06-26 /pmc/articles/PMC4081131/ /pubmed/25024919 http://dx.doi.org/10.7717/peerj.451 Text en © 2014 Lai et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited.
spellingShingle Gastroenterology and Hepatology
Lai, Pauline Siew Mei
Wong, Yin Yen
Low, Yong Chia
Lau, Hui Ling
Chin, Kin-Fah
Mahadeva, Sanjiv
Unexplained abdominal pain as a driver for inappropriate therapeutics: an audit on the use of intravenous proton pump inhibitors
title Unexplained abdominal pain as a driver for inappropriate therapeutics: an audit on the use of intravenous proton pump inhibitors
title_full Unexplained abdominal pain as a driver for inappropriate therapeutics: an audit on the use of intravenous proton pump inhibitors
title_fullStr Unexplained abdominal pain as a driver for inappropriate therapeutics: an audit on the use of intravenous proton pump inhibitors
title_full_unstemmed Unexplained abdominal pain as a driver for inappropriate therapeutics: an audit on the use of intravenous proton pump inhibitors
title_short Unexplained abdominal pain as a driver for inappropriate therapeutics: an audit on the use of intravenous proton pump inhibitors
title_sort unexplained abdominal pain as a driver for inappropriate therapeutics: an audit on the use of intravenous proton pump inhibitors
topic Gastroenterology and Hepatology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4081131/
https://www.ncbi.nlm.nih.gov/pubmed/25024919
http://dx.doi.org/10.7717/peerj.451
work_keys_str_mv AT laipaulinesiewmei unexplainedabdominalpainasadriverforinappropriatetherapeuticsanauditontheuseofintravenousprotonpumpinhibitors
AT wongyinyen unexplainedabdominalpainasadriverforinappropriatetherapeuticsanauditontheuseofintravenousprotonpumpinhibitors
AT lowyongchia unexplainedabdominalpainasadriverforinappropriatetherapeuticsanauditontheuseofintravenousprotonpumpinhibitors
AT lauhuiling unexplainedabdominalpainasadriverforinappropriatetherapeuticsanauditontheuseofintravenousprotonpumpinhibitors
AT chinkinfah unexplainedabdominalpainasadriverforinappropriatetherapeuticsanauditontheuseofintravenousprotonpumpinhibitors
AT mahadevasanjiv unexplainedabdominalpainasadriverforinappropriatetherapeuticsanauditontheuseofintravenousprotonpumpinhibitors